AMN Healthcare Services (NYSE:AMN – Get Free Report) and Biodesix (NASDAQ:BDSX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.
Earnings & Valuation
This table compares AMN Healthcare Services and Biodesix”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AMN Healthcare Services | $2.73 billion | 0.48 | -$95.70 million | $2.68 | 12.75 |
| Biodesix | $88.50 million | 3.23 | -$35.26 million | ($3.17) | -8.56 |
Analyst Ratings
This is a breakdown of recent recommendations for AMN Healthcare Services and Biodesix, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AMN Healthcare Services | 1 | 3 | 4 | 0 | 2.38 |
| Biodesix | 1 | 0 | 3 | 1 | 2.80 |
AMN Healthcare Services currently has a consensus target price of $36.00, indicating a potential upside of 5.39%. Biodesix has a consensus target price of $31.33, indicating a potential upside of 15.48%. Given Biodesix’s stronger consensus rating and higher probable upside, analysts clearly believe Biodesix is more favorable than AMN Healthcare Services.
Profitability
This table compares AMN Healthcare Services and Biodesix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AMN Healthcare Services | 3.06% | 19.92% | 5.93% |
| Biodesix | -26.97% | -788.19% | -30.33% |
Insider and Institutional Ownership
99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by company insiders. Comparatively, 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
AMN Healthcare Services has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, Biodesix has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.
Summary
AMN Healthcare Services beats Biodesix on 8 of the 15 factors compared between the two stocks.
About AMN Healthcare Services
AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including AMN Healthcare, Nursefinders, HealthSource Global Staffing, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is headquartered in Dallas, Texas.
About Biodesix
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Receive News & Ratings for AMN Healthcare Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMN Healthcare Services and related companies with MarketBeat.com's FREE daily email newsletter.
